IL188545A - Melanocortin receptor agonist compound, pharmaceutical composition comprising such a compound and use thereof in the manufacture of medicaments for treating disorders - Google Patents

Melanocortin receptor agonist compound, pharmaceutical composition comprising such a compound and use thereof in the manufacture of medicaments for treating disorders

Info

Publication number
IL188545A
IL188545A IL188545A IL18854508A IL188545A IL 188545 A IL188545 A IL 188545A IL 188545 A IL188545 A IL 188545A IL 18854508 A IL18854508 A IL 18854508A IL 188545 A IL188545 A IL 188545A
Authority
IL
Israel
Prior art keywords
cys
arg
phe
seq
trp
Prior art date
Application number
IL188545A
Other languages
English (en)
Other versions
IL188545A0 (en
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of IL188545A0 publication Critical patent/IL188545A0/en
Publication of IL188545A publication Critical patent/IL188545A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
IL188545A 2005-07-08 2008-01-02 Melanocortin receptor agonist compound, pharmaceutical composition comprising such a compound and use thereof in the manufacture of medicaments for treating disorders IL188545A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69777905P 2005-07-08 2005-07-08
US74885005P 2005-12-09 2005-12-09
PCT/US2006/026586 WO2007008704A2 (en) 2005-07-08 2006-07-10 Melanocortin receptor ligands

Publications (2)

Publication Number Publication Date
IL188545A0 IL188545A0 (en) 2008-04-13
IL188545A true IL188545A (en) 2011-08-31

Family

ID=37637790

Family Applications (3)

Application Number Title Priority Date Filing Date
IL188545A IL188545A (en) 2005-07-08 2008-01-02 Melanocortin receptor agonist compound, pharmaceutical composition comprising such a compound and use thereof in the manufacture of medicaments for treating disorders
IL201732A IL201732A (en) 2005-07-08 2009-10-25 Melanocortin receptor ligands
IL246392A IL246392A (en) 2005-07-08 2016-06-22 Melanocortin receptor ligands

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL201732A IL201732A (en) 2005-07-08 2009-10-25 Melanocortin receptor ligands
IL246392A IL246392A (en) 2005-07-08 2016-06-22 Melanocortin receptor ligands

Country Status (21)

Country Link
US (8) US8039435B2 (en:Method)
EP (6) EP2236151B1 (en:Method)
JP (4) JP4734411B2 (en:Method)
KR (2) KR101232201B1 (en:Method)
CN (5) CN103755786B (en:Method)
AU (2) AU2006269261B2 (en:Method)
BE (1) BE2021C557I2 (en:Method)
CA (4) CA2614615C (en:Method)
DK (4) DK3354273T3 (en:Method)
ES (4) ES2386862T3 (en:Method)
FR (1) FR21C1060I2 (en:Method)
HU (4) HUE037147T2 (en:Method)
IL (3) IL188545A (en:Method)
NL (1) NL301150I2 (en:Method)
NZ (2) NZ580806A (en:Method)
PL (4) PL2548568T3 (en:Method)
PT (4) PT2236151E (en:Method)
RU (2) RU2380372C2 (en:Method)
SG (1) SG163585A1 (en:Method)
SI (1) SI3354273T1 (en:Method)
WO (1) WO2007008704A2 (en:Method)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103755786B (zh) * 2005-07-08 2016-05-11 益普生制药股份有限公司 黑皮质素受体配体
DE102007020152A1 (de) * 2007-04-26 2008-10-30 Charité - Universitätsmedizin Berlin Mittel zur antiinfektiven Behandlung eines Patienten
EP2148692B1 (en) * 2007-05-25 2017-01-25 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
AR066175A1 (es) * 2007-06-15 2009-08-05 Sod Conseils Rech Applic Ligandos del receptor de melanocortina de peptidos ciclicos
EP2214693B1 (en) 2007-11-05 2015-09-09 Ipsen Pharma S.A.S. Use of melanocortins to treat insulin sensitivity
KR101810110B1 (ko) 2008-05-27 2017-12-18 젠자임 코포레이션 알파-멜라노사이트 자극 호르몬의 펩티드 유사체
EA018630B1 (ru) 2008-06-09 2013-09-30 Палатин Текнолоджиз, Инк. Специфичные к меланокортиновым рецепторам пептиды для лечения сексуальной дисфункции
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
WO2010144344A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Melanocortin receptor-specific peptides
JP2013501053A (ja) * 2009-08-05 2013-01-10 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ 脂質異常症を治療するためのメラノコルチンの使用
HUE031856T2 (en) * 2009-08-31 2017-08-28 Tensive Controls Inc Stabilized melanocortin ligands
WO2011060352A1 (en) * 2009-11-16 2011-05-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
RU2012125033A (ru) * 2009-11-16 2014-01-20 Ипсен Фарма С.А.С. СПОСОБ СИНТЕЗА Ас-Arg-ЦИКЛО(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
EA201290295A1 (ru) 2009-11-23 2013-01-30 Палатин Текнолоджиз, Инк. Специфичные к рецептору меланокортина-1 линейные пептиды
CN102725305B (zh) 2009-11-23 2016-08-24 帕拉丁科技公司 黑皮质素-1受体特异性环肽
KR102038677B1 (ko) * 2011-06-14 2019-10-30 입센 파마 에스.에이.에스 활성 성분으로 멜라노코르틴 수용체 리간드를 함유하는 지속-방출형 조성물
SI3539551T1 (sl) 2011-12-29 2022-02-28 Rhythm Pharmaceuticals, Inc. Postopek zdravljenja motenj povezanih z receptorjem melanokortin-4 v heterozigotnih nosilcih
EP2705835A1 (en) 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
RU2668791C2 (ru) * 2012-10-19 2018-10-02 ТиЭксПи ФАРМА ГМБХ АНАЛОГИ АЛЬФА- и ГАММА-MSH
US10232018B2 (en) 2013-03-14 2019-03-19 Mallinckrodt Ard Ip Limited ACTH for treatment of acute respiratory distress syndrome
CA2906694A1 (en) 2013-03-15 2014-09-18 Rhythm Metabolic, Inc. Peptide compositions
CN115957297A (zh) 2013-03-15 2023-04-14 节奏制药公司 药物组合物
CN106232623A (zh) 2014-04-22 2016-12-14 Txp制药股份有限公司 具有支链氨基酸探针的肽类似物
US10960046B2 (en) 2015-09-30 2021-03-30 Rhythm Pharmaceuticals, Inc. Method of treating melanocortin-4 receptor pathway-associated disorders
WO2018074999A1 (en) * 2016-10-17 2018-04-26 The Arizona Board Of Regents On Behalf Of The University Of Arizona Novel modulators of melanocortin receptors for the treatment of depression and anxiety
US11542302B2 (en) 2015-10-15 2023-01-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulators of melanocortin receptors for the treatment of depression and anxiety
US10653743B2 (en) * 2015-10-15 2020-05-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of depression and anxiety by a melanocortin 5 receptor antagonist, PG-20N
EP3596107A1 (en) * 2017-03-15 2020-01-22 Novo Nordisk A/S Bicyclic compounds capable of binding to melanocortin 4 receptor
AU2019249255A1 (en) 2018-04-06 2020-11-05 Alastair GARFIELD Compositions for treating kidney disease
US20210221867A1 (en) * 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor
CA3100868A1 (en) * 2018-05-23 2019-11-28 Provincial Health Services Authority Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy
US11396535B2 (en) 2019-03-01 2022-07-26 Provincial Health Services Authority Cyclic peptide analogs of melanocortin and amanitin and methods of making such
AR123603A1 (es) * 2020-09-24 2022-12-21 Rhythm Pharmaceuticals Inc Métodos de tratamiento de los trastornos asociados a la vía del receptor de melanocortina
AU2022242835A1 (en) * 2021-03-24 2023-10-05 Glo Pharma, Inc. Peptides and methods for reducing skin pigmentation
US20240287154A1 (en) * 2021-05-27 2024-08-29 The Regents Of The University Of Michigan Mc3r agonist peptides
EP4605077A1 (en) 2022-10-18 2025-08-27 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2025123056A1 (en) * 2023-12-07 2025-06-12 Endevica Bio, Inc. Non-naturally occurring melanocortin analogs and associated methods

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US613874A (en) 1898-11-08 George e
US1613874A (en) 1922-03-29 1927-01-11 Miner Inc W H Friction draft gear
US5652214A (en) 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
SE9700620D0 (sv) 1997-02-21 1997-02-21 Wapharm Ab Cykliska peptider med selektivitet för MSH-receptor subtyper
WO1999021571A1 (en) 1997-10-27 1999-05-06 Trega Biosciences, Inc. Melanocortin receptor ligands and methods of using same
AU3768799A (en) * 1998-04-28 1999-11-16 Trega Biosciences, Inc. Isoquinoline compound melanocortin receptor ligands and methods of using same
CA2337495C (en) * 1998-07-27 2008-03-18 Iowa State University Research Foundation Melanocortin-4 receptor gene and use as a genetic marker for fat content, weight gain, and/or feed consumption of animals
WO2000010507A2 (en) 1998-08-21 2000-03-02 The Children's Medical Center Corporation Use of melanin for inhibition of angiogenesis and macular degeneration
US6716810B1 (en) 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
US6603058B1 (en) 1998-12-09 2003-08-05 Oklahoma Medical Research Foundation Non-human animal model for obesity and uses thereof
EP1165613B1 (en) 1999-03-29 2008-04-30 The Procter & Gamble Company Melanocortin receptor ligands
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
CA2390723A1 (en) 1999-11-12 2001-05-17 Merck & Co., Inc. Melanocortin-3 receptor deficient cells, non-human transgenic animals and methods of selecting compounds which regulate body weight
US6600015B2 (en) 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
CN1440406A (zh) * 2000-06-28 2003-09-03 辉瑞产品公司 黑皮质素受体配体
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
MXPA03002160A (es) 2000-09-13 2004-05-04 Eleanor Roosevelt Inst Metodo para el tratamiento de resistencia a insulina en obesidad y diabetes.
US20030113263A1 (en) 2001-02-13 2003-06-19 Oregon Health And Sciences University, A Non-Profit Organization Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia
EP1363631A4 (en) 2001-03-02 2005-11-16 Bristol Myers Squibb Co "COMPOUNDS SUITED AS MODULATORS OF MELANOCORTIN RECEPTORS AND THESE PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF"
US6770645B2 (en) * 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
AU2002322466B2 (en) * 2001-07-11 2007-08-30 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US7034004B2 (en) 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
US20040128136A1 (en) * 2002-09-20 2004-07-01 Irani Pourang Polad Internet voice browser
CA2530024A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(mc4) agonists and their uses
WO2005000338A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Uses of melanocortin-3 receptor (mc3r) agonist peptides
US7084111B2 (en) 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
US7662771B2 (en) * 2003-08-20 2010-02-16 Emisphere Technologies, Inc. Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP)-1 compound or a melanocortin-4 receptor (MC4) agonist peptide
CA2530983C (en) * 2003-08-20 2012-09-25 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
WO2005040109A1 (en) * 2003-10-22 2005-05-06 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
DE10355559A1 (de) 2003-11-21 2005-06-23 Orthogen Ag Transskin
US20070155660A1 (en) 2003-12-10 2007-07-05 Marsh Donald J Inhibition of voluntary ethanol consumption with selective melanocortin 4-receptor agonists
WO2005102377A1 (en) * 2004-03-29 2005-11-03 Eli Lilly And Company Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion
CN101076348A (zh) 2004-10-08 2007-11-21 克里纽沃药物有限公司 用于在受试者中诱导黑素原生成的组合物和方法
WO2006073772A1 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
WO2006073771A2 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
CN103755786B (zh) * 2005-07-08 2016-05-11 益普生制药股份有限公司 黑皮质素受体配体
CN101273059B (zh) 2005-08-26 2014-02-19 艾伯维有限公司 治疗活性的α-MSH类似物

Also Published As

Publication number Publication date
ES2663916T3 (es) 2018-04-17
CN105837661B (zh) 2024-10-15
SI3354273T1 (sl) 2021-10-29
NZ565217A (en) 2010-03-26
HK1258965A1 (en) 2019-11-22
RU2380372C2 (ru) 2010-01-27
EP2236151B1 (en) 2012-05-23
JP5889513B2 (ja) 2016-03-22
WO2007008704A2 (en) 2007-01-18
NZ580806A (en) 2012-07-27
EP2286825A2 (en) 2011-02-23
EP3925614A2 (en) 2021-12-22
JP2009500427A (ja) 2009-01-08
ES2604328T3 (es) 2017-03-06
PT2236151E (pt) 2012-07-02
EP3925614A3 (en) 2022-03-23
AU2009230799A1 (en) 2009-11-19
CN101257916B (zh) 2013-04-03
ES2386862T3 (es) 2012-09-03
EP2286825A3 (en) 2011-07-27
US9850280B2 (en) 2017-12-26
WO2007008704A3 (en) 2007-10-11
EP2236151A1 (en) 2010-10-06
NL301150I2 (nl) 2022-11-24
US20200095281A1 (en) 2020-03-26
ES2877349T3 (es) 2021-11-16
SG163585A1 (en) 2010-08-30
CA3044795A1 (en) 2007-01-18
PL2548568T3 (pl) 2018-06-29
PL2286825T3 (pl) 2017-06-30
IL188545A0 (en) 2008-04-13
US20110183886A1 (en) 2011-07-28
KR100997177B1 (ko) 2010-11-29
EP2286825B1 (en) 2016-09-28
CN119119190A (zh) 2024-12-13
NL301150I1 (en:Method) 2021-12-08
KR20100016120A (ko) 2010-02-12
US20180105557A1 (en) 2018-04-19
FR21C1060I2 (fr) 2022-12-02
CA3228910A1 (en) 2007-01-18
CA2793119A1 (en) 2007-01-18
US20180305406A1 (en) 2018-10-25
HUE037147T2 (hu) 2018-08-28
CN105837661A (zh) 2016-08-10
PL3354273T3 (pl) 2021-10-11
US9458195B2 (en) 2016-10-04
RU2009131092A (ru) 2011-02-20
KR101232201B1 (ko) 2013-02-12
PT3354273T (pt) 2021-06-28
DK3354273T3 (da) 2021-06-28
FR21C1060I1 (fr) 2022-01-21
US20160368962A1 (en) 2016-12-22
RU2008104803A (ru) 2009-08-20
PT2286825T (pt) 2017-01-02
RU2439079C2 (ru) 2012-01-10
CN101676298A (zh) 2010-03-24
IL201732A (en) 2016-07-31
CN103755786B (zh) 2016-05-11
CA2614615A1 (en) 2007-01-18
CA2614615C (en) 2012-10-16
DK2548568T3 (en) 2018-03-12
EP3354273B1 (en) 2021-03-24
HUE031731T2 (en) 2017-07-28
IL246392A (en) 2017-07-31
EP1915167A4 (en) 2010-04-07
EP2548568A3 (en) 2013-07-17
EP3354273A1 (en) 2018-08-01
CN103755786A (zh) 2014-04-30
AU2006269261B2 (en) 2009-12-17
US8039435B2 (en) 2011-10-18
AU2009230799B2 (en) 2012-02-09
JP2015232003A (ja) 2015-12-24
EP1915167A2 (en) 2008-04-30
JP5965520B2 (ja) 2016-08-03
EP2548568A2 (en) 2013-01-23
DK2236151T3 (da) 2012-07-09
CN101257916A (zh) 2008-09-03
KR20080049711A (ko) 2008-06-04
HK1149190A1 (en) 2011-09-30
DK2286825T3 (en) 2017-01-09
HUE055154T2 (hu) 2021-11-29
IL201732A0 (en) 2010-06-16
BE2021C557I2 (en:Method) 2026-01-14
JP2013253090A (ja) 2013-12-19
US20170240595A1 (en) 2017-08-24
EP2548568B1 (en) 2018-01-10
US20220127305A1 (en) 2022-04-28
HUS2100054I1 (hu) 2021-12-28
JP4734411B2 (ja) 2011-07-27
AU2006269261A1 (en) 2007-01-18
US20100279922A1 (en) 2010-11-04
PL2236151T3 (pl) 2012-10-31
PT2548568T (pt) 2018-03-21
CA2793119C (en) 2019-07-23
JP2010090130A (ja) 2010-04-22

Similar Documents

Publication Publication Date Title
US20220127305A1 (en) Melanocortin receptor ligands
US20100173834A1 (en) Cyclic peptide melanocortin receptor ligands
US8349797B2 (en) Ligands of melanocortin receptors
HK40067409A (en) Melanocortin receptor ligands
HK1258965B (en) Melanocortin receptor ligands
HK1149190B (en) Melanocortin receptor ligands
HK1180596B (en) Melanocortin receptor ligands
HK1180596A (en) Melanocortin receptor ligands
HK1151246A (en) Melanocortin receptor ligands
HK1151246B (en) Melanocortin receptor ligands

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed